Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy

Lung Cancer

Volumn 56, Issue 3, 2007, Pages 377-381

  Dowlati, Afshin ^a   Subbiah, Shanmuga ^a   Cooney, Matthew ^a   Rutherford, Kimberly ^a   Mekhail, Tarek ^a   Fu, Pingfu ^a   Chapman, Robert ^a   Ness, Anne ^a   Cortas, Tania ^a   Saltzman, Joel ^a   Levitan, Nathan ^a   Warren, Gregory ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Phase II; Small cell lung cancer; Thalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG SCREENING; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HUMAN; LUNG EMBOLISM; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; WEAKNESS; XEROSTOMIA;

AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MICHIGAN; MIDDLE AGED; NEOPLASM STAGING; OHIO; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34247847775     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.01.020     Document Type: Article

References (23)

1. Johnson B.E., and Janne P.A. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am 18 (2004) 309-322
2. Hanna N.H., Sandler A.B., Loehrer P.J., Ansari R., Jung S.H., Lane K., et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 13 (2002) 95-102
3. Schiller J.H., Adak S., Cella D., DeVore III R.F., and Johnson D.H. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 2114-2122
4. Hanna N., Bunn Jr. P.A., Langer C., Einhorn L., Guthrie Jr. T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 (2006) 2038-2043
5. Niell H.B., Herndon J.E., Miller A.A., Watson D.M., Sandler A.B., Kelly K., et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23 (2005) 3752-3759
6. Giaccone G.C., Debruyne C., Felip E., Chapman P.B., Grant S.C., Millward M., et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 23 (2005) 6854-6864
7. Soria J.C., Johnson B.E., and Chevalier T.L. Imatinib in small cell lung cancer. Lung Cancer 41 Suppl. 1 (2003) S49-S53
8. Rudin C.M., Kozloff M., Hoffman P.C., Edelman M.J., Karnauskas R., Tomek R., et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22 (2004) 1110-1117
9. Salven P., Ruotsalainen T., Mattson K., and Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79 (1998) 144-146
10. Mall J.W., Schwenk W., Philipp A.W., Meyer-Kipker C., Mall W., Muller J., et al. Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase. Respirology 7 (2002) 99-102
11. Ruotsalainen T., Joensuu H., Mattson K., and Salven P. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomark Prev 11 (2002) 1492-1495
12. Litz J., Sakuntala Warshamana-Greene G., Sulanke G., Lipson K.E., and Krystal G.W. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 46 (2004) 283-291
13. Teo SK. AAPS J 22:E14-19; 2005.
14. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., and Tai Y.T. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 (2001) 210-216
15. Haslett P.A.J., Corral L.G., Albert M., and Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in CD8+ subset. J Exp Med 187 (1998) 1885-1892
16. Corral L.G., Haslett P.A.J., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 163 (1999) 380-386
17. Mall J.W., Philipp A.W., Mall W., and Pollmann C. Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy. Angiogenesis 5 (2002) 11-13
18. Mascaux C., Paesmans M., Berghmans T., Branle F., Lafitte J.J., Vallot F., et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30 (2000) 23-36
19. Therasse P., Arbuck S., Eisenhauer E., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
20. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
21. Pandya J., Levy D.E., Hidalgo M., Cohen R.B., Lee M.W., Schiller J.H., et al. A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report. J Clin Oncol 23 16S (2005) [2005 ASCO Annual Meeting Proceedings. Part I of II (June 1 Suppl.) abstract 7005]
22. Pujol J.L., Breton J.L., Gervais R., Tanguy M., Quoix E., David P., et al. A prospective randomized phase II, double blind, placebo-controlled study of thalidomide in extensive-disease small cell lung cancer patients after response to chemotherapy. J Clin Oncol 24 18S (2006) [2006 ASCO Annual Meeting Proceedings. Part I (June 20 Suppl.), abstract 7057]
23. Lee S.M., James L.E., Mohamed-Ali V., Boschoff C., Snee M., Brock C., et al. A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer. Proc Am Soc Clin Oncol 21 (2002) [abstract 1251]